- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 30, 2024Navigating Generational Dynamics
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
May 6, 2024Litigating with the Legends
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Merck Sharp & Dohme B.V. v. Warner Chilcott Co., LLC
A patent is obvious in view of the knowledge of one of skill in the art to disclose the gaps not inherently disclosed in the primary reference.
October 25, 2016
Case Name: Merck Sharp & Dohme B.V. v. Warner Chilcott Co., LLC, Civ. No. 13-2088-GMS, 2016 U.S. Dist. LEXIS 114419 (D. Del. Aug 26, 2016) (Sleet, J.)
Drug Product and Patent(s)-in-Suit: NuvaRing® (etonogestrel / ethinyl estradiol); U.S. Patent No. 5,989,581 (“the ’581 patent”)
Nature of the Case and Issue(s) Presented: The issue here centered on Warner’s defense that the ’581 patent was invalid based on anticipation and obviousness. For anticipation, Warner asserted that four different claim elements were inherently disclosed in a prior-art patent application that shared one of the same inventors of the ’581 patent. Warner further argued that those limitations, if not inherently disclosed, would have been obvious in light of the knowledge of one of skill in the art.
Merck argued that the ’581 patent was not anticipated because it was not inherent that all of the claim limitations were disclosed in the prior art. Further, it would not have been obvious to one of skill in the art because the prior-art reference taught away from the claimed limitations. Lastly, Merck asserted that secondary considerations of non-obviousness demonstrated that the patent was not obvious. The court held that the ’581 patent was not anticipated, but the patent was invalid as obvious.
Why Warner Prevailed: The district court found the ’581 patent was not anticipated because several of the claimed limitations were not disclosed in the prior-art reference. In particular, the court found that there was no clear and convincing evidence that two of the claim elements were explicitly or inherently disclosed in the prior art.
As to obviousness, the court found that these two limitations were obvious in light of the knowledge of one of skill in the art. The court rejected Merck’s argument that the prior art taught away from the claim limitations. Indeed, for one of the elements, the inventor of the ’581 patent admitted he relied on the knowledge of doctors regarding the release-timing claim limitation.
Lastly, the court rejected Merck’s argument that secondary considerations evidenced the non-obviousness of the patent-in-suit. The court found that there was no commercial success because NuvaRing was the fifth most popular contraceptive. Moreover, effective contraception was not the novel feature of the ’581 patent. Thus, the commercial success of NuvaRing was not relevant. Likewise, Merck’s allegations of copying were unfounded because of the ANDA legal framework. Lastly, Merck did not establish a nexus between long-felt need or industry recognition and the patented features.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.